Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 219-225

  Cross, Nicholas C P ^a,b   Hochhaus, Andreas ^c   Müller, Martin C ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL1 measurement; BCR ABL1 mRNA; Chronic myeloid leukemia

Indexed keywords

BCR ABL PROTEIN; ANTINEOPLASTIC AGENT; BCR-ABL1 FUSION PROTEIN, HUMAN; BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; GENE CONTROL; HOUSEKEEPING GENE; HUMAN; MINIMAL RESIDUAL DISEASE; MOLECULAR MONITORING; MONITORING; PRIORITY JOURNAL; QUALITY CONTROL; REMISSION; REVIEW; STANDARDIZATION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; BONE MARROW; CALIBRATION; DRUG MONITORING; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; STANDARD;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE MARROW; CALIBRATION; DRUG MONITORING; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; RNA, MESSENGER;

EID: 84925954652     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2315-1     Document Type: Review

References (37)

1. Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R (1990) Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A 87(2):563–567
2. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P (1989) Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation. Lancet 2(8672):1125–1128
3. Hughes TP, Goldman JM (1990) Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help? Bone Marrow Transplant 5(1):3–6
4. Cross NC, Hughes TP, Feng L, O’Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM (1993) Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 84(1):67–74
5. Cross NC (2009) Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):355–365. doi:10.1016/j.beha.2009.04.001
6. Hughes T, Janssen JW, Morgan G, Martiat P, Saglio G, Pignon JM, Pignatti FP, Mills K, Keating A, Gluckman E et al (1990) False-positive results with PCR to detect leukaemia-specific transcript. Lancet 335(8696):1037–1038
7. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82(6):1929–1936
8. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H (1993) Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 341(8840):275–276
9. Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B (1992) Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 82(4):701–707
10. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 91(1):126–131
11. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87(4):1549–1555
12. Lin F, Chase A, Bungey J, Goldman JM, Cross NC (1995) Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosom Cancer 13(2):110–114
13. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 17(12):2474–2486. doi:10.1038/sj.leu.2403136
14. Branford S, Hughes T (2006) Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 125:69–92
15. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J, Hughes T (2006) Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20(11):1925–1930. doi:10.1038/sj.leu.2404388
16. Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid S, Molecular Oncology Resource Committee of the College of American P (2012) Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med 136(1):33–40. doi:10.5858/arpa.2011-0136-OA
17. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 17(12):2318–2357. doi:10.1038/sj.leu.2403135
18. Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, de Castro DG, Austin S, Awan A, Burt E, Clench T, Farruggia J, Hancock J, Irvine AE, Kizilors A, Langabeer S, Milner BJ, Nickless G, Schuh A, Sproul A, Wang L, Wickham C, Cross NC (2011) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153(2):179–190. doi:10.1111/j.1365-2141.2011.08603.x
19. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STISG (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423–1432. doi:10.1056/NEJMoa030513
20. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28–37. doi:10.1182/blood-2006-01-0092
21. Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saussele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Muller MC (2014) Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1746-8
22. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175. doi:10.1038/leu.2012.104
23. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi:10.1182/blood-2013-05-501569
24. Cross NCP, White H, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Polakova KM, Dulucq S, Martinelli G, Leibundgut EO, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC et al. (2015) reference:Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. doi:10.1038/leu.2015.29
25. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8):3330–3338. doi:10.1182/blood-2008-04-150680
26. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23(11):1957–1963. doi:10.1038/leu.2009.168
27. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Muller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC (2010) Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 116(22):e111–e117. doi:10.1182/blood-2010-06-291641
28. White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Muller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E (2013) Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem 59(6):938–948. doi:10.1373/clinchem.2012.196477
29. Cayuela JM, Macintyre E, Darlington M, Abdelali RB, Fund X, Villarese P, Tulliez M, Raffoux E, Sigaux F, Rea D, Seror V (2011) Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica 96(5):664–671. doi:10.3324/haematol.2010.034389
30. Maute C, Nibourel O, Rea D, Coiteux V, Grardel N, Preudhomme C, Cayuela JM, on behalf of G (2014) Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale. Clin Biochem. doi:10.1016/j.clinbiochem.2014.05.067
31. White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikiene E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedeu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajic T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Muller MC, Hochhaus A, Schimmel H, Cross NC, Emons H (2015) A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real time quantitative PCR. Leukemia 29(2):369–376. doi:10.1038/leu.2014.217
32. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215. doi:10.1182/blood-2010-12-326405
33. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24(10):1719–1724. doi:10.1038/leu.2010.185
34. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA (2010) Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 32(6 Pt 1):e222–e228. doi:10.1111/j.1751-553X.2010.01236.x
35. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV (2010) In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 116(8):1329–1335. doi:10.1182/blood-2009-11-255109
36. Goh HG, Lin M, Fukushima T, Saglio G, Kim D, Choi SY, Kim SH, Lee J, Lee YS, Oh SM, Kim DW (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 52(5):896–904. doi:10.3109/10428194.2011.555569
37. Jennings LJ, George D, Czech J, Yu M, Joseph L (2014) Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16(2):174–179. doi:10.1016/j.jmoldx.2013.10.007